At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
DermoRelizema ecofoamdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Open Label, Uncontrolled Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam in the Management of Some Dermatitis in the Adult
In Brief
A clinical study evaluating DermoRelizema ecofoam for Dermatitis. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The scope of this open label clinical trial is to evaluate and confirm the performance of DermoRelizema ecofoam in the improvement of the dermatitis severity, by alleviating the symptomatology. The disease severity will be clinically measured through the Investigator Global Assessment (IGA) after 28 days of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartMay 2021
Primary CompletionJan 2022
TodayJul 2026
First PostedApr 1, 2021
Enrollment StartMay 13, 2021
Primary CompletionJan 5, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.3 years ago
Interventions
DermoRelizema ecofoamdevice
DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration